Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-[(1S,2S,5S)-5-(hydroxymethyl)-8-methyl-3‑oxabicyclo[3.3.1]non‑7‑en‑2‑yl]phenol is a synthetic small molecule with the molecular formula C16H20O3 and a molecular weight of approximately 260.33 g/mol[1][6]. It is classified as a phenolic compound due to its phenol moiety and features a complex bicyclic structure with defined stereochemistry[9]. The compound has been cataloged in chemical databases such as PubChem (CID: 6852154), DrugBank (DB07086), and ChEMBL (CHEMBL193676)[1][6][3]. It is considered an experimental drug and has not received regulatory approval for any indication; there are no reported clinical trials or approved uses as of the latest updates[3][8]. Its mechanism of action and therapeutic potential remain uncharacterized in public sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-[(1S,2S,5S)-5-(hydroxymethyl)-8-methyl-3-oxabicyclo[3.3.1]non-7-en-2-yl]phenol.